Biochemical markers of bone metabolism: Application to understanding bone remodeling in children and adolescents

Journal of Pediatric Endocrinology and Metabolism

Volumn 16, Issue SUPPL. 3, 2003, Pages 661-672

  Levine, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Collagen cross links; N telepeptides; Osteocalcin; Osteoporosis; Rickets

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; OSTEOCALCIN; TETRACYCLINE;

ADOLESCENT; AGE; ARTICLE; BONE BIOPSY; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; CHILD; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; GENDER; GROWTH RATE; HUMAN; METABOLIC BONE DISEASE; METABOLIC PARAMETERS; OSSIFICATION; OSTEOLYSIS; PROTEIN STRUCTURE; PUBERTY;

ADOLESCENT; AGE FACTORS; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DEVELOPMENT; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; CHILD; COLLAGEN TYPE I; FEMALE; HOMEOSTASIS; HUMANS; MALE; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; SEX FACTORS; TIME FACTORS;

EID: 0141891916     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Seibel MJ, Woitge HW. Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects. J Clin Densitom 1999; 2: 299-321.
2. Russell RG. The assessment of bone metabolism in vivo using biochemical approaches. Horm Metab Res 1997; 29: 138-144.
3. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000; 11: 281-294.
4. Schonau E, Rauch F. Markers of bone and collagen metabolism - problems and perspectives in paediatrics. Horm Res 1997; 48 (Suppl 5): 50-59.
5. Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 2000; 46: 431.
6. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 1999; 140: 332-337.
7. Thorsen K, Kristoffersson A, Lorentzon R. The effects of brisk walking on markers of bone and calcium metabolism in postmenopausal women. Calcif Tissue Int 1996; 58: 221-225.
8. Malaval L, Modrowski D, Gupta AK, Aubin JE. Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures. J Cell Physiol 1994; 158: 555-572.
9. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem 1994; 55: 287-299.
10. Ash P, Loutit JF, Townsend KM. Osteoclasts derived from haematopoietic stem cells. Nature 1980; 283: 669-670.
11. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999; 106: 167-170.
12. Weir EC, Lowik CW, Paliwal I, Insogna KL. Colony stimulating factor-I plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related protein. J Bone Miner Res 1996; 11: 1474-1481.
13. Lacey DL, Erdmann JM, Teitelbaum SL, Tan HL, Ohara J, Shioi A. Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology 1995; 136: 2367-2376.
14. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-311.
15. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994; 55: 273-286.
16. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001.
17. Lean JM, Matsuo K, Fox SW, Fuller K, Gibson FM, Draycott G, Wani MR, Bayley KE, Wong BR, Choi Y, Wagner EF, Chamber TJ. Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. Bone 2000; 27: 29-40.
18. Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T. Regulation of osteoclast differentiation and function by receptor activator of NFκB ligand and osteoprotegerin. Anat Rec 2002; 268: 137-146.
19. Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001; 145: 61-64.
20. Khosla S. Minireview: The OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050-5055.
21. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-615.
22. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347: 175-184.
23. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002; 11: 2119-2127.
24. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24: 45-48.
25. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002; 17: 26-29.
26. Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med 2001; 33: 7-21.
27. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64: 403-434.
28. Lapillonne A, Travers R, DiMaio M, Salle BL, Glorieux FH. Urinary excretion of cross-linked N-telopeptides of type I collagen to assess bone resorption in infants from birth to 1 year of age. Pediatrics 2002; 110: 105-109.
29. van der Sluis IM, Hop WC, van Leeuwen JP, Pols HA, de Muinck Keizer-Schrama SM. A cross-sectional study on biochemical parameters of bone turnover and vitamin D metabolites in healthy Dutch children and young adults. Horm Res 2002; 57: 170-179.
30. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy X ray absorptiometry in white children and young adults. Arch Dis Child 2002; 87: 341-347.
31. Mora S, Pitukcheewanont P, Kaufman FR, Nelson JC, Gilsanz V. Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999; 14: 1664-1671.
32. Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SC, Weber G, Abbiati G, Chiumello G. Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int 1998; 63: 369-374.
33. Garnero P, Somay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 337-349.
34. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8: 881-889.
35. Christiansen C, Riis BJ, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; i: 1105-1108.
36. Christiansen C, Riis BJ, Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos Int 1990; 1: 35-40.
37. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992; 74: 481-486.
38. Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin N Am 1994; 20: 589-607.
39. Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995; 41: 1560-1566.
40. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993; 77: 1046-1053.
41. Hill CS, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 1990; 186: 315-320.
42. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328-1332.
43. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact aminoterminal propeptide of human type I procollagen. Clin Chem 1996; 42: 947-954.
44. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641-649.
45. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH 3rd, Eyre DR. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994; 9: 135-142.
46. Kruse K, Kracht U. Evaluation of serum osteocalcin as an index of altered bone metabolism. Eur J Pediatr 1986; 145: 27-33.
47. Daniels ED, Pettifor JM, Moodley GP. Serum osteocalcin has limited usefulness as a diagnostic marker for rickets. Eur J Pediatr 2000; 159: 730-733.
48. Robins SP. Biochemical markers for assessing skeletal growth. Eur J Clin Nutr 1994; 48 (Suppl 1): S199-S209.
49. Cowell CT, Wuster C. The effects of growth hormone deficiency and growth hormone replacement therapy on bone. A meeting report. Horm Res 2000; 54 (Suppl 1): 68-74.
50. Cowell CT, Woodhead HJ, Brody J. Bone markers and bone mineral density during growth hormone treatment in children with growth hormone deficiency. Horm Res 2000; 54 (Suppl 1): 44-51.
51. Saggese G, Baroncelli GI. Bone status in children and adolescents with growth hormone deficiency: effect of growth hormone treatment. Int J Clin Pract Suppl 2002; 18-21.
52. Baroncelli GI, Bertelloni S, Ceccarelli C, Cupelli D, Saggese G. Dynamics of bone turnover in children with GH deficiency treated with GH until final height. Eur J Endocrinol 2000; 142: 549-556.
53. Tobiume H, Kanzaki S, Hida S, Ono T, Moriwake T, Yamauchi S, Tanaka H, Seino Y. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 1997; 82: 2056-2061.
54. Sartorio A, Conti A, Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad Med J 1993; 69: 846-850.